Interleukin-6 as a Biomarker for Breast Cancer Prognosis and Therapeutic Response

Seerwan Hamadameen Sulaiman; Hozan I. Ibrahim

doi:10.25212/lfu.qzj.9.3.49

Authors

Seerwan Hamadameen Sulaiman Department of Medical Laboratory Science, College of Health Science, Lebanese French University, Erbil, Kurdistan Region, Iraq.
Hozan I. Ibrahim Department of Medical Laboratory Science, College of Health Science, Lebanese French University, Erbil, Kurdistan Region, Iraq.

DOI:

https://doi.org/10.25212/lfu.qzj.9.3.49

Keywords:

Interleukin-6, Breast cancer, STAT, signaling pathways, cancer therapy

Abstract

The pleiotropic cytokine known as Interleukin-6 (IL-6) is a crucial component in the genesis and progression of breast cancer. It does this by acting on several signaling pathways at once, which has an impact on many different elements of tumor biology. The activation of signaling cascades that speed up cell cycle progression and prevent apoptosis is thought to be how IL-6 promotes tumor growth and proliferation. Furthermore, IL-6 promotes angiogenesis, which aids in the tumor's development of additional blood vessels microenvironment. The proliferation, survival, and therapeutic resistance of cancer cells are all made possible downstream signaling pathways including JAK/STAT as well as MAPK are activated. Additionally, this cytokine promotes the epithelial-mesenchymal transition (EMT), further supporting tumor metastasis and invasion. Furthermore, within controlling immune responses and encouraging an immunosuppressive environment, IL-6 has an impact on the tumor microenvironment

Downloads

Download data is not yet available.

References

Arihiro, K., Oda, H., Kaneko, M., & Inai, K. (2000). Cytokines facilitate chemotactic motility of breast carcinoma cells. Breast cancer, 7, 221-230.

Aryappalli, P., Shabbiri, K., Masad, R. J., Al-Marri, R. H., Haneefa, S. M., Mohamed, Y. A., ... & Al-Ramadi, B. K. (2019).

Barbieri, I., Pensa, S., Pannellini, T., Quaglino, E., Maritano, D., Demaria, M., ... & Poli, V. (2010). Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer research, 70(6), 2558-2567.

Barre, A., Culerrier, R., Granier, C., Selman, L., Peumans, W. J., Van Damme, E. J., ... & Rougé, P. (2009). Mapping of IgE-binding epitopes on the major latex allergen Hev b 2 and the cross-reacting 1, 3β-glucanase fruit allergens as a molecular basis for the latex-fruit syndrome. Molecular immunology, 46(8-9), 1595-1604.

Bharti, R., Dey, G., Ojha, P. K., Rajput, S., Jaganathan, S. K., Sen, R., & Mandal, M. (2016). Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene, 35(30), 3965-3975.

Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M, Altunbas H, Akan I, Savas B (2004) Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 27(2–3):58–65

Bouaouiche, S., Ghione, S., Sghaier, R., Burgy, O., Racoeur, C., Derangère, V., ... & Plenchette, S. (2021). Nitric oxide-releasing drug glyceryl trinitrate targets JAK2/STAT3 signaling, migration and invasion of triple-negative breast cancer cells. International Journal of Molecular Sciences, 22(16), 8449.

Casneuf, T., Axel, A. E., King, P., AlvarezBromberg, J., & Wang, T. C. (2009). Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer cell, 15(2), 79-80.

Chien, C. M., Lin, K. L., Su, J. C., Chuang, P. W., Tseng, C. H., Chen, Y. L., ... & Lin, S. R. (2010). Naphtho [1, 2-b] furan-4, 5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor/PI3K/Akt signaling pathway. European journal of pharmacology, 636(1-3), 52-58.

Choi, H. S., Kim, J. H., Kim, S. L., Deng, H. Y., Lee, D., Kim, C. S., ... & Lee, D. S. (2018). Catechol derived from aronia juice through lactic acid bacteria fermentation inhibits breast cancer stem cell formation via modulation Stat3/IL‐6 signaling pathway. Molecular Carcinogenesis, 57(11), 1467-1479.

Deisseroth, A., Ko, C. W., Nie, L., Zirkelbach, J. F., Zhao, L., Bullock, J., ... & Pazdur, R. (2015). FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clinical Cancer Research, 21(5), 950-954.

Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005). Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical Cancer Research, 11(2), 728-734.

Dethlefsen, C., Højfeldt, G., & Hojman, P. (2013). The role of intratumoral and systemic IL-6 in breast cancer. Breast cancer research and treatment, 138(3), 657-664.

Di Cosimo, S., Esgueva Colmenarejo, A. J., Morancho Armisen, B., Cortes Castan, J., Arribas Lopez, J. V., Bernado Morales, C., ... & Zacarias Fluck, M. F. (2016). Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 2016, vol. 7, núm. 42, p. 1-67956-67965.

Do, E. J., Hwang, S. W., Kim, S. Y., Ryu, Y. M., Cho, E. A., Chung, E. J., ... & Myung, S. J. (2016). Suppression of colitis‐associated carcinogenesis through modulation of IL‐6/STAT3 pathway by balsalazide and VSL# 3. Journal of gastroenterology and hepatology, 31(8), 1453-1461.

Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014, February). The two faces of IL-6 in the tumor microenvironment. In Seminars in immunology (Vol. 26, No. 1, pp. 38-47). Academic Press.

Ghorbani, M., Sabzichi, M., Ramezani, F., & Mohammadian, J. (2019). Adjuvant therapy with stattic enriches the anti-proliferative effect of doxorubicin in human ZR-75-1 breast cancer cells via arresting cell cycle and inducing apoptosis. Biomedicine & Pharmacotherapy, 109, 1240-1248.

Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012). Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer treatment reviews, 38(7), 904-910.

Jiang, X. P., Yang, D. C., Elliott, R. L., & Head, J. F. (2000). Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. Cytokine, 12(5), 458-465.

Jiang, X. P., Yang, D. C., Elliott, R. L., & Head, J. F. (2011). Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. Anticancer research, 31(9), 2899-2906.

Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Müller-Newen, G., & Schaper, F. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical journal, 374(1), 1-20.

Hu, Y., Yagüe, E., Zhao, J., Wang, L., Bai, J., Yang, Q., ... & Zhang, J. (2018). Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer letters, 423, 47-59.

Hunter, C. A., & Jones, S. A. (2015). IL-6 as a keystone cytokine in health and disease. Nature immunology, 16(5), 448-457.

Huang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., ... & Wang, Y. (2020). Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?. European Journal of Medicinal Chemistry, 187, 111922.

Lamy, S., Akla, N., Ouanouki, A., Lord-Dufour, S., & Béliveau, R. (2012). Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Experimental cell research, 318(13), 1586-1596.

Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial–mesenchymal transition. Nature reviews Molecular cell biology, 15(3), 178-196.

Lederle, W., Depner, S., Schnur, S., Obermueller, E., Catone, N., Just, A., ... & Mueller, M. M. (2011). IL‐6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. International journal of cancer, 128(12), 2803-2814.

Li, H., Xiao, H., Lin, L., Jou, D., Kumari, V., Lin, J., & Li, C. (2014). Drug design targeting protein–protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. Journal of medicinal chemistry, 57(3), 632-641.

Liang, F., Ren, C., Wang, J., Wang, S., Yang, L., Han, X., ... & Yang, G. (2019). The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Oncogenesis, 8(10), 59.

Lin, C., Liao, W., Jian, Y., Peng, Y., Zhang, X., Ye, L., ... & Song, L. (2017). CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling. Oncogene, 36(26), 3695-3705.

Lin, S., Gan, Z., Han, K., Yao, Y., & Min, D. (2015). Interleukin-6 as a prognostic marker for breast cancer: a meta-analysis. Tumori Journal, 101(5), 535-541.

Liu, L. C., Wu, Y. C., Kuo, S. C., Ho, C. T., Way, T. D., & Chen, S. T. (2018). 2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial–to–Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells. Anticancer research, 38(5), 2849-2859.

Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., ... & Wicha, M. S. (2011). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer research, 71(2), 614-624.

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018). Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature reviews Clinical oncology, 15(4), 234-248.

J. D., Werbeck, J. L., Verhulst, T., ... & Sasser, A. K. (2016). Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer: Targets and Therapy, 13-27.

Kim, B. H., Yi, E. H., Li, Y. C., Park, I. C., Park, J. Y., & Ye, S. K. (2019). Anticancer activity of tubulosine through suppression of interleukin-6-induced janus kinase 2/signal transducer and activation of transcription 3 signaling. Journal of Breast Cancer, 22(3), 362-374.

Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., & O'Shea, J. J. (2012). Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Current opinion in pharmacology, 12(4), 464-470.

Kozłowski, L., Zakrzewska, I., Tokajuk, P., & Wojtukiewicz, M. Z. (2003). Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Roczniki Akademii Medycznej w Bialymstoku (1995), 48, 82-84

Madden, K. S., Szpunar, M. J., & Brown, E. B. (2011). β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines. Breast cancer research and treatment, 130, 747-758.

Martínez-Pérez, C., Kay, C., Meehan, J., Gray, M., Dixon, J. M., & Turnbull, A. K. (2021). The IL6-like cytokine family: Role and biomarker potential in breast cancer. Journal of personalized medicine, 11(11), 1073.

Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., & Jadidi-Niaragh, F. (2018). The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomedicine & Pharmacotherapy, 108, 1415-1424.

Michaud-Levesque, J., Bousquet-Gagnon, N., & Béliveau, R. (2012). Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Experimental cell research, 318(8), 925-935.

Miura, T., Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Takahashi, H., ... & Ochiai, A. (2015). Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas, 44(5), 756-763.

Moen, A., Schistad, E. I., Rygh, L. J., Røe, C., & Gjerstad, J. (2014). Role of IL1A rs1800587, IL1B rs1143627 and IL1RN rs2234677 genotype regarding development of chronic lumbar radicular pain; a prospective one-year study. PLoS One, 9(9), e107301

Morancho, B., Zacarías-Fluck, M., Esgueva, A., Bernadó-Morales, C., Di Cosimo, S., Prat, A., ... & Rubio, I. T. (2016). Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 7(42), 67956.

Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., ... & Hamamoto, R. (2000). An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology, 59(2), 166-173.

Noori, S., Tavirani, M. R., Deravi, N., Rabbani, M. I. M., & Zarghi, A. (2020). Naringenin enhances the anti-cancer effect of cyclophosphamide against MDA-MB-231 breast cancer cells via targeting the STAT3 signaling pathway. Iranian journal of pharmaceutical research: IJPR, 19(3), 122.

Oh, E., Kim, Y. J., An, H., Sung, D., Cho, T. M., Farrand, L., ... & Kim, J. Y. (2018). Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition. International journal of cancer, 143(8), 1978-1993.

Payton, E., Khubchandani, J., Thompson, A., & Price, J. H. (2017). Parents’ expectations of high schools in firearm violence prevention. Journal of community health, 42, 1118-1126.

Ricciardi, M., Zanotto, M., Malpeli, G., Bassi, G., Perbellini, O., Chilosi, M., ... & Krampera, M. (2015). Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. British journal of cancer, 112(6), 1067-1075.

Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., ... & Panés, J. (2017). OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 376(18), 1723-1736.

Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., ... & Bonafè, M. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. The Journal of clinical investigation, 117(12), 3988-4002.

Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006). Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chemistry & biology, 13(11), 1235-1242.

Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011). The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1813(5), 878-888.

Sharma, R., & Vinayak, M. (2011). α-Tocopherol attenuates NF-κB activation and pro-inflammatory cytokine IL-6 secretion in cancer-bearing mice. Bioscience Reports, 31(5), 421-428.

Shi, W., Yan, D., Zhao, C., Xiao, M., Wang, Y., Ma, H., ... & Lin, L. (2017). Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista. Biochemical and biophysical research communications, 491(1), 159-165.

Siersbæk, R., Scabia, V., Nagarajan, S., Chernukhin, I., Papachristou, E. K., Broome, R., ... & Carroll, J. S. (2020). IL6/STAT3 signaling hijacks estrogen receptor α enhancers to drive breast cancer metastasis. Cancer Cell, 38(3), 412-423.

Steward, W. P., & Brown, K. (2013). Cancer chemoprevention: a rapidly evolving field. British journal of cancer, 109(1), 1-7.

Taudorf, S., Krabbe, K. S., Berg, R. M. G., Møller, K., Pedersen, B. K., & Bruunsgaard, H. (2008). Common studied polymorphisms do not affect plasma cytokine levels upon endotoxin exposure in humans. Clinical & Experimental Immunology, 152(1), 147-152.

Tawara, K., Oxford, J. T., & Jorcyk, C. L. (2011). Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer management and research, 177-189.

Tian, J., Chen, X., Fu, S., Zhang, R., Pan, L., Cao, Y., ... & Lin, J. (2019). Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast cancer research and treatment, 175, 553-566.

Tsoi, H., Man, E. P., Chau, K. M., & Khoo, U. S. (2021). Targeting the IL-6/STAT3 signalling cascade to reverse tamoxifen resistance in estrogen receptor positive breast cancer. Cancers, 13(7), 1511.

Vyas, D., Lopez-Hisijos, N., Shah, P., Deshpande, K. S., Basson, M. D., Vyas, A., & Chaturvedi, L. S. (2017). A second-generation proteasome inhibitor and doxorubicin modulates IL-6, pSTAT-3 and NF-kB activity in MDA-MB-231 breast Cancer cells. Journal of nanoscience and nanotechnology, 17(1), 175-185.

Wollenhaupt, J., Lee, E. B., Curtis, J. R., Silverfield, J., Terry, K., Soma, K., ... & Cohen, S. (2019). Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis research & therapy, 21(1), 1-18.

Rosean, T. R., Tompkins, V. S., Tricot, G., Holman, C. J., Olivier, A. K., Zhan, F., & Janz, S. (2014). Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunologic research, 59, 188-202.

Wang, Y., Ma, H., Zhao, C., Liu, T., Yan, D., Jou, D., ... & Lin, L. (2017). Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling. Oncotarget, 8(20), 33683.

Wang, T., Fahrmann, J. F., Lee, H., Li, Y. J., Tripathi, S. C., Yue, C., ... & Yu, H. (2018). JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell metabolism, 27(1), 136-150.

Wolf, J., Rose-John, S., & Garbers, C. (2014). Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine, 70(1), 11-20.

Yang, X. M., Wang, Y. S., Zhang, J., Li, Y., Xu, J. F., Zhu, J., ... & Wiedemann, P. (2009). Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1α and VEGF in laser-induced rat choroidal neovascularization. Investigative ophthalmology & visual science, 50(4), 1873-1879.

Yang, F., Hu, M., Lei, Q., Xia, Y., Zhu, Y., Song, X., ... & Wei, Y. (2015). Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell death & disease, 6(3), e1701-e1701.

Yokoe, T., lino, Y., & Morishita, Y. (2000). Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer, 7, 187-190.

Zhong, H., Davis, A., Ouzounova, M., Carrasco, R. A., Chen, C., Breen, S., ... & Hollingsworth, R. E. (2016). A novel IL6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors. Cancer research, 76(2), 480-490.